• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

免疫检查点抑制剂:胃肠病学家需要了解的知识。

Checkpoint inhibitors: What gastroenterologists need to know.

机构信息

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Thomas Jefferson University, Philadelphia, PA 19107, United States.

出版信息

World J Gastroenterol. 2018 Dec 28;24(48):5433-5438. doi: 10.3748/wjg.v24.i48.5433.

DOI:10.3748/wjg.v24.i48.5433
PMID:30622372
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6319137/
Abstract

Checkpoint inhibitors are increasingly being used in clinical practice. They can cause various gastrointestinal, hepatic and pancreatic side effects. As these side effects can be serious, appropriate management is essential. The different checkpoint inhibitors with their mechanisms of action and indications, as well as evaluation and management of gastrointestinal, hepatic and pancreatic side effects, are discussed in this article.

摘要

检查点抑制剂在临床实践中越来越多地被使用。它们会引起各种胃肠道、肝脏和胰腺的副作用。由于这些副作用可能很严重,因此适当的管理是必不可少的。本文讨论了不同的检查点抑制剂及其作用机制和适应证,以及胃肠道、肝脏和胰腺副作用的评估和管理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d03/6319137/98236e177918/WJG-24-5433-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d03/6319137/98236e177918/WJG-24-5433-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d03/6319137/98236e177918/WJG-24-5433-g001.jpg

相似文献

1
Checkpoint inhibitors: What gastroenterologists need to know.免疫检查点抑制剂:胃肠病学家需要了解的知识。
World J Gastroenterol. 2018 Dec 28;24(48):5433-5438. doi: 10.3748/wjg.v24.i48.5433.
2
New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity.NCCN 指南更新:免疫治疗相关毒性的识别与管理。
J Natl Compr Canc Netw. 2018 May;16(5S):594-596. doi: 10.6004/jnccn.2018.0047.
3
Dermatologic adverse events of checkpoint inhibitors: what an oncologist should know.检查点抑制剂的皮肤不良事件:肿瘤学家应了解的内容。
Immunotherapy. 2016 Dec;8(12):1437-1446. doi: 10.2217/imt-2016-0074.
4
Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management.免疫检查点抑制剂引起的内分泌功能障碍:诊断和临床管理的实用建议。
Cancer. 2018 Mar 15;124(6):1111-1121. doi: 10.1002/cncr.31200. Epub 2018 Jan 3.
5
Toxicity patterns associated with chemotherapy/immune checkpoint inhibitor combinations: a meta-analysis.化疗/免疫检查点抑制剂联合治疗相关的毒性模式:一项荟萃分析。
Immunotherapy. 2019 Apr;11(6):543-554. doi: 10.2217/imt-2018-0186.
6
Immune checkpoint inhibitors: a narrative review of considerations for the anaesthesiologist.免疫检查点抑制剂:麻醉医师考虑因素的叙述性综述。
Br J Anaesth. 2020 Mar;124(3):251-260. doi: 10.1016/j.bja.2019.11.034. Epub 2020 Jan 29.
7
Immune checkpoint inhibitors renal side effects and management.免疫检查点抑制剂的肾脏副作用及管理
Immunotherapy. 2016 Dec;8(12):1417-1425. doi: 10.2217/imt-2016-0099.
8
Immune checkpoint inhibitors side effects and management.免疫检查点抑制剂的副作用及管理
Immunotherapy. 2016 Jun;8(7):799-807. doi: 10.2217/imt-2016-0029.
9
Graft rejection after immune checkpoint inhibitor therapy in solid organ transplant recipients.实体器官移植受者接受免疫检查点抑制剂治疗后的移植物排斥反应。
Acta Oncol. 2018 Oct;57(10):1414-1418. doi: 10.1080/0284186X.2018.1479069. Epub 2018 Jun 18.
10
Toxicities associated with checkpoint inhibitors-an overview.与检查点抑制剂相关的毒性-概述。
Rheumatology (Oxford). 2019 Dec 1;58(Suppl 7):vii7-vii16. doi: 10.1093/rheumatology/kez418.

引用本文的文献

1
Acute Oncologic Complications: Clinical-Therapeutic Management in Critical Care and Emergency Departments.急性肿瘤并发症:重症监护和急诊科的临床治疗管理。
Curr Oncol. 2023 Aug 2;30(8):7315-7334. doi: 10.3390/curroncol30080531.
2
Hepatotoxicity in immune checkpoint inhibitors: A pharmacovigilance study from 2014-2021.免疫检查点抑制剂的肝毒性:一项 2014-2021 年的药物警戒研究。
PLoS One. 2023 Mar 7;18(3):e0281983. doi: 10.1371/journal.pone.0281983. eCollection 2023.
3
Case Report: Exacerbation of varices following atezolizumab plus bevacizumab treatment of hepatocellular carcinoma: A case series and literature review.

本文引用的文献

1
Tim-3 expression and its role in hepatocellular carcinoma.Tim-3 的表达及其在肝细胞癌中的作用。
J Hematol Oncol. 2018 Oct 11;11(1):126. doi: 10.1186/s13045-018-0667-4.
2
TIGIT: a novel immunotherapy target moving from bench to bedside.TIGIT:从实验室走向临床的新型免疫治疗靶点
Cancer Immunol Immunother. 2018 Nov;67(11):1659-1667. doi: 10.1007/s00262-018-2246-5. Epub 2018 Sep 19.
3
Management of adverse events related to checkpoint inhibition therapy.与检查点抑制疗法相关的不良事件的管理。
病例报告:阿替利珠单抗联合贝伐单抗治疗肝细胞癌后静脉曲张加重:病例系列及文献综述
Front Oncol. 2022 Jul 22;12:948293. doi: 10.3389/fonc.2022.948293. eCollection 2022.
4
Therapeutic and Systemic Adverse Events of Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 axis for Clinical Management of NSCLC.免疫检查点抑制剂针对 PD-1/PD-L1 轴在 NSCLC 临床治疗中的治疗和全身不良事件。
Cell Transplant. 2021 Jan-Dec;30:9636897211041587. doi: 10.1177/09636897211041587.
5
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.癌症免疫治疗学会(SITC)免疫检查点抑制剂相关不良反应临床实践指南。
J Immunother Cancer. 2021 Jun;9(6). doi: 10.1136/jitc-2021-002435.
6
Atezolizumab, a PD-L1 Inhibitor: An Association of Bleeding Gastric Ulcer With Its Use.阿替利珠单抗,一种程序性死亡受体配体1(PD-L1)抑制剂:其使用与出血性胃溃疡的关联。
Cureus. 2021 Jun 14;13(6):e15637. doi: 10.7759/cureus.15637.
7
Checkpoint Inhibitors and Hepatotoxicity.检查点抑制剂与肝毒性
Biomedicines. 2021 Jan 21;9(2):101. doi: 10.3390/biomedicines9020101.
8
Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: A single-center analysis.实体器官移植受者转移性癌症患者接受免疫检查点抑制剂治疗的临床结局:单中心分析。
Cancer. 2020 Nov 1;126(21):4780-4787. doi: 10.1002/cncr.33134. Epub 2020 Aug 12.
Memo. 2018;11(2):132-137. doi: 10.1007/s12254-018-0416-y. Epub 2018 Jun 12.
4
Delivery Strategies for Immune Checkpoint Blockade.免疫检查点阻断的递送策略。
Adv Healthc Mater. 2018 Oct;7(20):e1800424. doi: 10.1002/adhm.201800424. Epub 2018 Jul 5.
5
Anti-PD-1 Therapy-Associated Perforating Colitis.抗程序性死亡蛋白1(PD-1)治疗相关的穿孔性结肠炎
Case Rep Gastrointest Med. 2018 May 31;2018:3406437. doi: 10.1155/2018/3406437. eCollection 2018.
6
Pembrolizumab-Induced Microscopic Colitis.帕博利珠单抗诱导的显微镜下结肠炎。
Am J Gastroenterol. 2018 Apr;113(4):629-630. doi: 10.1038/ajg.2018.8.
7
Downregulation of BTLA on NKT Cells Promotes Tumor Immune Control in a Mouse Model of Mammary Carcinoma.NKT 细胞上 BTLA 的下调促进乳腺癌小鼠模型中的肿瘤免疫控制。
Int J Mol Sci. 2018 Mar 7;19(3):752. doi: 10.3390/ijms19030752.
8
Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management.免疫检查点抑制相关的结肠炎:症状、内镜特征、组织学及治疗反应
ESMO Open. 2018 Jan 13;3(1):e000278. doi: 10.1136/esmoopen-2017-000278. eCollection 2018.
9
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.纳武利尤单抗联合伊匹单抗治疗错配修复缺陷/微卫星高度不稳定转移性结直肠癌的持久临床获益。
J Clin Oncol. 2018 Mar 10;36(8):773-779. doi: 10.1200/JCO.2017.76.9901. Epub 2018 Jan 20.
10
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.与免疫检查点阻断相关的免疫相关不良事件。
N Engl J Med. 2018 Jan 11;378(2):158-168. doi: 10.1056/NEJMra1703481.